Want to see JP:4892 full AI Analyst Report?
Total Valuation
Cyfuse Biomedical K.K. has a market cap or net worth of ¥5.45B. The enterprise value is ¥2.22B.
Market Cap¥5.45B
Enterprise Value¥2.22B
Share Statistics
Cyfuse Biomedical K.K. has 10,091,200 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding10,091,200
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Cyfuse Biomedical K.K.’s return on equity (ROE) is -0.28 and return on invested capital (ROIC) is -20.35%.
Return on Equity (ROE)-0.28
Return on Assets (ROA)-0.18
Return on Invested Capital (ROIC)-20.35%
Return on Capital Employed (ROCE)-0.24
Revenue Per Employee10.04M
Profits Per Employee-33.21M
Employee Count23
Asset Turnover0.05
Inventory Turnover1.72
Valuation Ratios
The current PE Ratio of Cyfuse Biomedical K.K. is ―. Cyfuse Biomedical K.K.’s PEG ratio is 0.34.
PE Ratio―
PS Ratio22.48
PB Ratio1.88
Price to Fair Value1.88
Price to FCF-8.92
Price to Operating Cash Flow0.00
PEG Ratio0.34
Income Statement
In the last 12 months, Cyfuse Biomedical K.K. had revenue of 231.00M and earned -763.84M in profits. Earnings per share was -86.78.
Revenue231.00M
Gross Profit78.40M
Operating Income-828.18M
Pretax Income-761.30M
Net Income-763.84M
EBITDA-792.68M
Earnings Per Share (EPS)-86.78
Cash Flow
In the last 12 months, operating cash flow was 0.00 and capital expenditures 0.00, giving a free cash flow of 0.00 billion.
Operating Cash Flow0.00
Free Cash Flow0.00
Free Cash Flow per Share0.00
Dividends & Yields
Cyfuse Biomedical K.K. pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.57
52-Week Price Change-20.24%
50-Day Moving Average570.22
200-Day Moving Average605.11
Relative Strength Index (RSI)46.60
Average Volume (3m)50.89K
Important Dates
Cyfuse Biomedical K.K. upcoming earnings date is Aug 14, 2026, TBA (Confirmed).
Last Earnings DateMay 15, 2026
Next Earnings DateAug 14, 2026
Ex-Dividend Date―
Financial Position
Cyfuse Biomedical K.K. as a current ratio of 4.54, with Debt / Equity ratio of 45.05%
Current Ratio4.54
Quick Ratio4.44
Debt to Market Cap0.25
Net Debt to EBITDA3.05
Interest Coverage Ratio-58.00
Taxes
In the past 12 months, Cyfuse Biomedical K.K. has paid 2.54M in taxes.
Income Tax2.54M
Effective Tax Rate>-0.01
Enterprise Valuation
Cyfuse Biomedical K.K. EV to EBITDA ratio is -3.51, with an EV/FCF ratio of -4.77.
EV to Sales12.03
EV to EBITDA-3.51
EV to Free Cash Flow-4.77
EV to Operating Cash Flow-5.20
Balance Sheet
Cyfuse Biomedical K.K. has ¥3.53B in cash and marketable securities with ¥1.24B in debt, giving a net cash position of ¥2.30B billion.
Cash & Marketable Securities¥3.53B
Total Debt¥1.24B
Net Cash¥2.30B
Net Cash Per Share¥227.48
Tangible Book Value Per Share¥312.91
Margins
Gross margin is 39.30%, with operating margin of -358.52%, and net profit margin of -330.67%.
Gross Margin39.30%
Operating Margin-358.52%
Pretax Margin-329.57%
Net Profit Margin-330.67%
EBITDA Margin-343.16%
EBIT Margin-358.52%
Analyst Forecast
The average price target for Cyfuse Biomedical K.K. is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast246.42%
EPS Growth Forecast9.39%